Literature DB >> 14551536

Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer.

Yun Zhang1, Felix Schlachetzki, Jian Yi Li, Ruben J Boado, William M Pardridge.   

Abstract

PURPOSE: The transfer of exogenous genes to the entire retina and other ocular structures is possible with a vascular route of gene delivery using a non-viral gene transfer method. The present studies examine the extent to which either beta-galactosidase or luciferase expression plasmids are targeted to the retina in the adult rhesus monkey following intravenous administration. In addition, these studies examine the pattern of organ expression of the transgene in the rhesus monkey depending on whether the plasmid is under the influence of a widely expressed promoter, the SV40 promoter, or an ocular-specific promoter, the opsin promoter.
METHODS: The plasmid DNA with either the SV40 or opsin promoter is encapsulated in the interior of 85 nm pegylated immunoliposomes (PILs), which are targeted across the blood-retinal barrier and into ocular cells with a monoclonal antibody to the human insulin receptor. Following a single intravenous injection of the PIL carrying the transgene, the animals were sacrificed 2, 7, or 14 days later for the measurement of beta-galactosidase or luciferase gene expression in the monkey eye and peripheral organs.
RESULTS: Histochemistry showed expression of the beta-galactosidase gene throughout the entire primate retina including the photoreceptor cells with either an SV40 or a bovine opsin promoter. Whereas the SV40 promoter enables gene expression in other organs of the primate (brain, liver, spleen), the opsin promoter restricted trans-gene expression to the primate eye, as there was no gene expressed in other organs. The retinal luciferase activity at 2 days after administration was 9.6+/-0.4 pg luciferase/mg protein, and at 14 days after administration was still comparable to maximal levels of luciferase gene expression in the mouse or rat. Confocal microscopy with antibodies to the insulin receptor and to beta-galactosidase demonstrated co-localization in the retina, with high expression of the trans-gene and the insulin receptor in the inner segments of the photoreceptor cells.
CONCLUSIONS: The PIL non-viral gene transfer technology makes possible adult transgenics in 24 h. Ectopic expression of exogenous genes in organs other than the target organ is made possible with the use of organ specific promoters, and gene expression in the primate is restricted to the eye when the trans-gene is under the influence of the opsin promoter. Plasmid-based gene expression is still in the therapeutic range for 2-3 weeks after a single intravenous administration. Exogenous genes are expressed throughout the entire primate retina following the delivery of the gene to the eye via a trans-vascular route.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551536

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  22 in total

Review 1.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 2.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

3.  Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Authors:  Milan Raska; Zina Moldoveanu; Jan Novak; Zdenek Hel; Lea Novak; Jadranka Bozja; Richard W Compans; Chinglai Yang; Jiri Mestecky
Journal:  Vaccine       Date:  2008-02-07       Impact factor: 3.641

Review 4.  Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 5.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

Review 6.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

Authors:  Chun Chu; Yun Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 8.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

Review 9.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

10.  Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.

Authors:  Yun Zhang; William M Pardridge
Journal:  Pharm Res       Date:  2008-12-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.